Skip to Main Content

Good morning, one and all. Damian Garde here, filling in for Ed Silverman once again as another working week wends to a close. Here’s hoping you have something diverting planned for the other side of the whistle, whether a summer trip, a local jaunt, or just a few days away from blinking screens. Below are some tidbits to start your day, and, as always, do let us know if you hear something interesting. …

California Gov. Gavin Newsom wants the state to manufacture its own low-cost insulin to offset the rising prices of diabetes care, CNN informs us. The state has allocated $100 million for the project, with half paying for the construction of a manufacturing facility and the rest going toward development costs. Civica Rx, a nonprofit, announced a similar plan earlier this year, promising to sell insulin for no more than $30 a vial starting in 2024.


AbbVie used President Trump’s signature tax overhaul to shield the majority of its revenues from federal taxes, the Washington Post notes. According to a Senate Finance Committee investigation, AbbVie generated 75% of its sales from the U.S. in 2020 but reported only 1% of that as taxable income. Senate Democrats say AbbVie is just one example of how multinational corporations are exploiting legal loopholes to shield their profits from domestic taxation.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment

There was an error saving your display name. Please check and try again.